Since HDTs against TB are most likely to be deployed in the settings of multidrug-resistant TB (MDR-TB) and HIV coinfection, here, we focused on the effect of IDO inhibition in the M. tuberculosis/HIV coinfection setting in our RM model, adjunctive to cART. Here, IDO1 is linked to tuberculosis.